Skip to main content

Clarification: Oct 1, 2003

Premium

CLARIFICATION — In the BioArray News article, “Mike Hunkapiller, ABI, Stay Mum On Details of its Expression Array System,” published on Sept. 24, 2003, reported that Applied Biosystems President Mike Hunkapiller said the company’s patent, US Patent No. 6,573,089, “Method for using and making a fiber array,” referred to a next-generation microarray. In fact, in a later discussion, a company spokeswoman said Hunkapiller was referencing the company’s announced Expression Array System as next-generation microarray technology — not the technology described in US Patent No. 6,573,089. “Patent No. 6,573,089 is not for a next-generation microarray technology,” a company spokeswoman said in an e-mail message. BioArray News is pleased to make the clarification.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.